Saatja: "ECDC respiratory viruses" <
[email protected]>
Teema: UPDATED URL - FOR INFORMATION: A new version of ERVISS is now available
Kuupäev: 2024-11-13 10:47
Tähelepanu! Tegemist on väljastpoolt asutust saabunud kirjaga. Tundmatu
saatja korral palume linke ja faile mitte avada.
The mail below is being resent with a corrected URL to access ERVISS -
https://erviss.org/. Many thanks to those of you who informed us the
previous one was incorrect and please accept our apologies for the
inconvenience.
To: National Focal Points for Viral Respiratory Diseases, Operational
Contact Points for COVID-19, Influenza and SARI
Cc: National Coordinators , National Focal Points for Surveillance
Dear colleagues,
A new and improved version of the European Respiratory Virus Surveillance
Summary (ERVISS v2.0) is now available! Access it at https://erviss.org/
There are several new visualisations across ERVISS:
* Updated weekly summary of the epidemiological/virological situation for
Influenza, SARS-CoV-2 and RSV
* New country section - a single page providing the user with an overview of
the main indicators submitted by each country, together with a table
describing the underlying national surveillance systems used to collect
these data.
* RSV type data is now shown where reported. This is visible when only RSV
is selected.
* More age-specific data is now shown especially for primary care
surveillance data. These additional visualisations are possible due to the
countries switching to reporting age-specific data to RESPIAGGR. This is
visible when a single pathogen is selected.
* More detailed age distributions of hospitalised patients with SARI (severe
acute respiratory infection) testing positive for Influenza, SARS-CoV-2 and
RSV are shown in a new tab (‘Severity’ section 🡪 'SARI virological in
detail' tab).
* Antiviral susceptibility data for influenza viruses are now be included.
* Additional heatmaps showing the relative contribution of weekly data by
country. This is visible when a single pathogen is selected.
In addition to the new visualisations, the following improvements have been
implemented:
* Updated nomenclature for the different surveillance systems in the
Methods, tab headings and introductions to better reflect the way in which
data are collected in across different EU/EEA countries. (We will update to
reflect WHO/EURO countries and areas)
* Updated calculation for influenza dominant type means this information is
available for a greater number of weeks, including when influenza activity
is lower.
* Narrowed time range of data to the current season plus four historical
seasons to speed up and simply display of historical data.
Please remember to use the selection buttons on ERVISS to access all the new
visualisations (e.g. pathogen selector, age selector). Some detailed plots
are only visible when a single pathogen is selected.
Kind regards,
The ECDC and WHO Europe Respiratory Viruses Teams
Classified as ECDC NORMAL
From: ECDC respiratory viruses
Sent: 12 November 2024 13:49
Cc: ECDC Info <
[email protected]>
Subject: FOR INFORMATION: A new version of ERVISS is now available
To: National Focal Points for Viral Respiratory Diseases, Operational
Contact Points for COVID-19, Influenza and SARI
Cc: National Coordinators , National Focal Points for Surveillance
Dear colleagues,
A new and improved version of the European Respiratory Virus Surveillance
Summary (ERVISS v2.0) is now available! Access it at
<https://ecdc365.sharepoint.com/teams/iorg_dpr_rvl/Storage/Respiratory%20Viruses/Surveillance/Communication/Network_support/erviss.org>
erviss.org.
There are several new visualisations across ERVISS:
* Updated weekly summary of the epidemiological/virological situation for
Influenza, SARS-CoV-2 and RSV
* New country section - a single page providing the user with an overview of
the main indicators submitted by each country, together with a table
describing the underlying national surveillance systems used to collect
these data.
* RSV type data is now shown where reported. This is visible when only RSV
is selected.
* More age-specific data is now shown especially for primary care
surveillance data. These additional visualisations are possible due to the
countries switching to reporting age-specific data to RESPIAGGR. This is
visible when a single pathogen is selected.
* More detailed age distributions of hospitalised patients with SARI (severe
acute respiratory infection) testing positive for Influenza, SARS-CoV-2 and
RSV are shown in a new tab (‘Severity’ section 🡪 'SARI virological in
detail' tab).
* Antiviral susceptibility data for influenza viruses are now be included.
* Additional heatmaps showing the relative contribution of weekly data by
country. This is visible when a single pathogen is selected.
In addition to the new visualisations, the following improvements have been
implemented:
* Updated nomenclature for the different surveillance systems in the
Methods, tab headings and introductions to better reflect the way in which
data are collected in across different EU/EEA countries. (We will update to
reflect WHO/EURO countries and areas)
* Updated calculation for influenza dominant type means this information is
available for a greater number of weeks, including when influenza activity
is lower.
* Narrowed time range of data to the current season plus four historical
seasons to speed up and simply display of historical data.
Please remember to use the selection buttons on ERVISS to access all the new
visualisations (e.g. pathogen selector, age selector). Some detailed plots
are only visible when a single pathogen is selected.
Kind regards,
The ECDC and WHO Europe Respiratory Viruses Teams
DC NORMAL
Confidentiality Notice
If you are not the intended recipient of this message, you are hereby kindly
requested, to, consecutively, refrain from disclosing its content to any
third party, delete it and inform its sender of the erroneous transmittal.